Market Analysis and Price Projections for the Drug NDC: 16571-0692
Introduction
The drug with the National Drug Code (NDC) 16571-0692, identified as Carbidopa, Levodopa, and Entacapone, is a crucial medication for the treatment of Parkinson's disease. This analysis will delve into the current market dynamics, pricing trends, and future projections for this drug.
Current Market Overview
Manufacturer and Labeler
The drug NDC 16571-0692 is manufactured and labeled by Rising Pharma Holdings, Inc., a company that produces a wide range of pharmaceuticals, including generic and branded medications[1].
Drug Usage and Demand
Carbidopa, Levodopa, and Entacapone are essential for managing Parkinson's disease symptoms. The demand for this medication is consistent due to the chronic nature of the disease and the lack of a cure. This stability in demand makes it a significant product in the pharmaceutical market.
Pricing Trends
Historical Price Changes
The pricing of prescription drugs, including those manufactured by Rising Pharma Holdings, Inc., has seen significant fluctuations over the years. According to recent reports, the percentage of drugs with price increases has decreased, but the average percent of increase remains above the consumer price index (CPI-U)[4].
For the period between 2018 and 2022, the average percent of increase for prescription drugs was around 10.79%, which is higher than the CPI-U for 2022. However, generic drugs, which include many formulations of Carbidopa, Levodopa, and Entacapone, have seen a decrease in prices, with an average percent decrease of 49.21% for multisource generic drugs[4].
Wholesale Acquisition Cost (WAC) and Average Transaction Price
The Wholesale Acquisition Cost (WAC) or "list price" of drugs is a key metric in understanding pricing trends. For drugs like NDC 16571-0692, the WAC can vary, but it is generally higher than the average transaction price paid by payers due to discounts and rebates negotiated by pharmacy benefits managers (PBMs)[2][4].
Regulatory Impact
Medicare Drug Price Negotiation Program
Beginning in January 2026, the Medicare Drug Price Negotiation Program will introduce negotiated prices for certain drugs, including some that have seen significant price increases. This program aims to make prescription drugs more affordable for Medicare enrollees and taxpayers. Negotiated prices are expected to result in discounts ranging from 38% to 79% compared to list prices[2].
FDA Regulations and NDC Directory
The FDA's National Drug Code Directory ensures that all drugs, including those manufactured by Rising Pharma Holdings, Inc., are properly listed and regulated. This directory is crucial for maintaining transparency and compliance in the pharmaceutical industry[5].
Future Price Projections
Impact of Negotiated Prices
For drugs selected under the Medicare Drug Price Negotiation Program, significant price reductions are anticipated. Although NDC 16571-0692 is not explicitly mentioned in the initial list of negotiated drugs, future expansions of the program could potentially include this medication, leading to lower prices for Medicare enrollees[2].
Market Competition and Generic Pricing
The generic drug market is highly competitive, and prices tend to decrease as more generic versions of a drug become available. Given that Carbidopa, Levodopa, and Entacapone have multiple generic formulations, it is likely that prices will continue to be driven down by market competition[4].
Technological and Regulatory Advancements
Advancements in clinical trial designs, precision medicine, and AI/ML technologies are expected to reshape the biopharma and biotech industries. These innovations could lead to more efficient drug development and potentially lower costs, which may influence the pricing of existing medications like NDC 16571-0692[3].
Key Takeaways
- Stable Demand: The demand for Carbidopa, Levodopa, and Entacapone remains consistent due to the chronic nature of Parkinson's disease.
- Pricing Trends: Historical price changes show a decrease in the percentage of drugs with price increases, but generic drugs have seen significant price decreases.
- Regulatory Impact: The Medicare Drug Price Negotiation Program and FDA regulations will continue to influence pricing and transparency.
- Future Projections: Anticipated price reductions through negotiated prices and market competition are likely to impact the pricing of NDC 16571-0692.
FAQs
Q: What is the current manufacturer of the drug NDC 16571-0692?
A: The drug NDC 16571-0692 is manufactured and labeled by Rising Pharma Holdings, Inc.[1].
Q: How have prescription drug prices changed over the past few years?
A: The percentage of drugs with price increases has decreased, but the average percent of increase remains above the CPI-U. Generic drugs have seen significant price decreases[4].
Q: What is the impact of the Medicare Drug Price Negotiation Program on drug prices?
A: The program is expected to result in discounts ranging from 38% to 79% compared to list prices for selected drugs, starting in January 2026[2].
Q: How do FDA regulations affect the pricing and transparency of pharmaceuticals?
A: FDA regulations, including the National Drug Code Directory, ensure compliance and transparency in the pharmaceutical industry, which can influence pricing and market dynamics[5].
Q: What are the potential future price projections for NDC 16571-0692?
A: Future prices may be influenced by negotiated prices under the Medicare program, market competition, and advancements in drug development technologies[2][3][4].
Sources
- Find-A-Code: Rising Pharma Holdings, Inc. - List of Drugs.
- ASPE - HHS.gov: Medicare Drug Price Negotiation Program.
- TFS CRO: 5 Predictions for the Biopharma and Biotech Industries in 2025.
- Maine Health Data Organization: Rx Transparency Report 2024.
- FDA: National Drug Code Directory.
